The unfortunate irony is that an inversion makes it easier for an American company to invest in the U.S. and less likely that it will face competitive tax disadvantages — or be acquired by a foreign competitor.
We appreciate that the issues raised by U.S. tax reform are difficult. And we know that many good minds are working to reform the system.
While that process unfolds, we will remain focused on developing innovative medicines that significantly improve the lives of patients.
We want patients to have access to medicines and have expanded our assistance program to four times the federal poverty level so that more patients in need are eligible to receive their Pfizer medicines for free.
The Pfizer-Allergan combination is good for America.